|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SPRR2A |
Gene summary for SPRR2A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SPRR2A | Gene ID | 6700 |
| Gene name | small proline rich protein 2A | |
| Gene Alias | SPRR2A | |
| Cytomap | 1q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0007275 | UniProtAcc | P35326 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6700 | SPRR2A | LZE22T | Human | Esophagus | ESCC | 1.25e-02 | 1.10e+00 | 0.068 |
| 6700 | SPRR2A | P1T-E | Human | Esophagus | ESCC | 5.70e-10 | 4.25e+00 | 0.0875 |
| 6700 | SPRR2A | P4T-E | Human | Esophagus | ESCC | 1.51e-04 | 7.20e-01 | 0.1323 |
| 6700 | SPRR2A | P20T-E | Human | Esophagus | ESCC | 1.85e-07 | 2.02e+00 | 0.1124 |
| 6700 | SPRR2A | P23T-E | Human | Esophagus | ESCC | 1.18e-31 | 4.09e+00 | 0.108 |
| 6700 | SPRR2A | P39T-E | Human | Esophagus | ESCC | 4.34e-27 | 2.72e+00 | 0.0894 |
| 6700 | SPRR2A | P42T-E | Human | Esophagus | ESCC | 5.06e-23 | 2.28e+00 | 0.1175 |
| 6700 | SPRR2A | P47T-E | Human | Esophagus | ESCC | 1.46e-08 | 1.41e+00 | 0.1067 |
| 6700 | SPRR2A | P54T-E | Human | Esophagus | ESCC | 6.61e-03 | 7.90e-01 | 0.0975 |
| 6700 | SPRR2A | P74T-E | Human | Esophagus | ESCC | 1.21e-04 | 8.21e-01 | 0.1479 |
| 6700 | SPRR2A | P84T-E | Human | Esophagus | ESCC | 5.36e-07 | 2.22e+00 | 0.0933 |
| 6700 | SPRR2A | P126T-E | Human | Esophagus | ESCC | 4.86e-02 | 1.72e+00 | 0.1125 |
| 6700 | SPRR2A | P127T-E | Human | Esophagus | ESCC | 7.47e-31 | 2.93e+00 | 0.0826 |
| 6700 | SPRR2A | P128T-E | Human | Esophagus | ESCC | 2.71e-16 | 1.90e+00 | 0.1241 |
| 6700 | SPRR2A | C57 | Human | Oral cavity | OSCC | 9.13e-91 | 5.25e+00 | 0.1679 |
| 6700 | SPRR2A | C08 | Human | Oral cavity | OSCC | 2.88e-05 | 1.85e+00 | 0.1919 |
| 6700 | SPRR2A | LP15 | Human | Oral cavity | LP | 3.15e-04 | 1.59e+00 | 0.2174 |
| 6700 | SPRR2A | EOLP-1 | Human | Oral cavity | EOLP | 4.14e-10 | -4.80e-01 | -0.0202 |
| 6700 | SPRR2A | EOLP-2 | Human | Oral cavity | EOLP | 1.98e-08 | -4.70e-01 | -0.0203 |
| 6700 | SPRR2A | NEOLP-1 | Human | Oral cavity | NEOLP | 1.14e-04 | -4.15e-01 | -0.0194 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00435888 | Esophagus | ESCC | skin development | 163/8552 | 263/18723 | 6.48e-08 | 1.14e-06 | 163 |
| GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
| GO:000991310 | Esophagus | ESCC | epidermal cell differentiation | 122/8552 | 202/18723 | 1.69e-05 | 1.51e-04 | 122 |
| GO:00302167 | Esophagus | ESCC | keratinocyte differentiation | 86/8552 | 139/18723 | 8.53e-05 | 6.19e-04 | 86 |
| GO:00435887 | Oral cavity | OSCC | skin development | 143/7305 | 263/18723 | 2.77e-07 | 4.27e-06 | 143 |
| GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
| GO:00302166 | Oral cavity | OSCC | keratinocyte differentiation | 81/7305 | 139/18723 | 3.16e-06 | 3.81e-05 | 81 |
| GO:00099139 | Oral cavity | OSCC | epidermal cell differentiation | 109/7305 | 202/18723 | 1.08e-05 | 1.14e-04 | 109 |
| GO:000854416 | Oral cavity | LP | epidermis development | 112/4623 | 324/18723 | 3.81e-05 | 5.61e-04 | 112 |
| GO:004358816 | Oral cavity | LP | skin development | 93/4623 | 263/18723 | 6.47e-05 | 8.70e-04 | 93 |
| GO:003021613 | Oral cavity | LP | keratinocyte differentiation | 51/4623 | 139/18723 | 1.05e-03 | 8.84e-03 | 51 |
| GO:000991315 | Oral cavity | LP | epidermal cell differentiation | 69/4623 | 202/18723 | 1.53e-03 | 1.19e-02 | 69 |
| GO:000854424 | Oral cavity | EOLP | epidermis development | 64/2218 | 324/18723 | 2.48e-05 | 3.68e-04 | 64 |
| GO:003021621 | Oral cavity | EOLP | keratinocyte differentiation | 32/2218 | 139/18723 | 1.52e-04 | 1.62e-03 | 32 |
| GO:000991323 | Oral cavity | EOLP | epidermal cell differentiation | 39/2218 | 202/18723 | 1.38e-03 | 9.56e-03 | 39 |
| GO:004358822 | Oral cavity | EOLP | skin development | 48/2218 | 263/18723 | 1.49e-03 | 1.01e-02 | 48 |
| GO:003021631 | Oral cavity | NEOLP | keratinocyte differentiation | 32/2005 | 139/18723 | 2.16e-05 | 3.57e-04 | 32 |
| GO:000854431 | Oral cavity | NEOLP | epidermis development | 57/2005 | 324/18723 | 1.13e-04 | 1.35e-03 | 57 |
| GO:004358831 | Oral cavity | NEOLP | skin development | 48/2005 | 263/18723 | 1.56e-04 | 1.77e-03 | 48 |
| GO:000991331 | Oral cavity | NEOLP | epidermal cell differentiation | 38/2005 | 202/18723 | 3.92e-04 | 3.64e-03 | 38 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SPRR2A | SNV | Missense_Mutation | c.103C>T | p.Pro35Ser | p.P35S | P35326 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SPRR2A | SNV | Missense_Mutation | c.216N>T | p.Lys72Asn | p.K72N | P35326 | protein_coding | tolerated_low_confidence(0.54) | possibly_damaging(0.772) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SPRR2A | SNV | Missense_Mutation | c.62N>A | p.Pro21Gln | p.P21Q | P35326 | protein_coding | tolerated_low_confidence(0.26) | possibly_damaging(0.466) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SPRR2A | SNV | Missense_Mutation | c.156G>T | p.Gln52His | p.Q52H | P35326 | protein_coding | deleterious_low_confidence(0) | benign(0.146) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SPRR2A | SNV | Missense_Mutation | rs201645175 | c.58A>G | p.Thr20Ala | p.T20A | P35326 | protein_coding | tolerated_low_confidence(0.31) | benign(0) | TCGA-EO-A22T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SPRR2A | SNV | Missense_Mutation | novel | c.98N>A | p.Pro33His | p.P33H | P35326 | protein_coding | tolerated_low_confidence(0.66) | probably_damaging(0.951) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SPRR2A | SNV | Missense_Mutation | novel | c.191N>T | p.Gln64Leu | p.Q64L | P35326 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.803) | TCGA-DD-AACI-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SPRR2A | SNV | Missense_Mutation | c.104C>A | p.Pro35His | p.P35H | P35326 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-EP-A2KA-01 | Liver | liver hepatocellular carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | sorafenib | PD | |
| SPRR2A | SNV | Missense_Mutation | c.97C>A | p.Pro33Thr | p.P33T | P35326 | protein_coding | tolerated_low_confidence(0.64) | possibly_damaging(0.708) | TCGA-55-8511-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SPRR2A | SNV | Missense_Mutation | rs759301202 | c.112N>T | p.Pro38Ser | p.P38S | P35326 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.595) | TCGA-F1-A448-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |